Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,769
archived clinical trials in
Migraine Headaches

Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Oklahoma City, OK
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Smithfield, PA
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Smithfield, PA
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Mount Pleasant, SC
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Mount Pleasant, SC
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Chattanooga, TN
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Memphis, TN
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Dallas, TX
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
North Richland Hills, TX
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
North Richland Hills, TX
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Bellevue, WA
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Bellevue, WA
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Birmingham, AL
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Phoenix, AZ
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Little Rock, AR
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Carlsbad, CA
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Carlsbad, CA
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Orange, CA
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Orange, CA
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Oxnard, CA
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Oxnard, CA
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Palo Alto, CA
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Santa Monica, CA
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Colorado Springs, CO
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
New London, CT
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
New London, CT
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Tampa, FL
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
West Palm Beach, FL
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Decatur, GA
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Decatur, GA
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Champaign, IL
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Champaign, IL
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Chicago, IL
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Anderson, IN
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Anderson, IN
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Des Moines, IA
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Des Moines, IA
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Overland Park, KA
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Overland Park, KA
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Prairie Village, KA
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Prairie Village, KA
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Wichita, KA
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Wichita, KA
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Marrero, LA
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Marrero, LA
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Waldorf, MD
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Waldorf, MD
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
North Attleboro, MA
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
North Attleboro, MA
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Watertown, MA
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Watertown, MA
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Ann Arbor, MI
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Flowood, MS
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Flowood, MS
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Saint Louis, MO
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Saint Peters, MO
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Saint Peters, MO
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Springfield, MO
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Springfield, MO
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Las Vegas, NV
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Lebanon, NH
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Lebanon, NH
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Princeton, NJ
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Princeton, NJ
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Albuquerque, NM
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Brooklyn, NY
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
New York, NY
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Plainview, NY
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Plainview, NY
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Rochester, NY
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Durham, NC
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
High Point, NC
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
High Point, NC
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Scottdale, PA
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Scottdale, PA
Click here to add this to my saved trials